Fungicide Formulation Stability via Lactamide Mediator

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional formulations of oxathiapiprolin and metalaxyl-M fungicides face challenges in stability over time and increased toxicity, particularly at varying temperatures and high active ingredient loads.

Innovation Solution

A composition comprising oxathiapiprolin, metalaxyl-M, and a lactamide compound, with the lactamide compound making up at least 40% of the formulation, which enhances temperature stability and reduces toxicity, including eye irritancy, by optimizing the ratio of active ingredients and incorporating emulsifiers and dispersing agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If conventional formulation approaches are used for oxathiapiprolin and metalaxyl-M mixture, then formulation can be made, but stability over time is insufficient

Engineering Contradiction:
Improveformulation stabilityVSAvoidstability over time
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

The patent introduces a specific solvent system comprising dimethyl amide ether and lactic acid dimethyl amide as intermediary substances that mediate between the two active ingredients oxathiapiprolin and metalaxyl-M. This solvent system acts as a bridge to ensure compatibility and stability of the mixture over time, resolving the formulation stability issue without requiring complex multi-component systems.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Quantity of substance

If amount of active ingredients is increased, then fungicidal efficacy is improved, but toxicity becomes more complex to deal with

Engineering Contradiction:
Improveamount of active ingredientsVSAvoidtoxicity
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent optimizes the concentration parameters of the solvent system components (dimethyl amide ether and lactic acid dimethyl amide) to achieve a balance where high amounts of active ingredients can be formulated while maintaining acceptable toxicity levels. By carefully controlling the solvent composition ratios and concentrations, the formulation achieves both high active ingredient content and reduced eye irritancy.

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If high amount of metalaxyl-M is included, then temperature stability is optimized, but formulation complexity increases

Engineering Contradiction:
Improvetemperature stabilityVSAvoidformulation complexity
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent creates a composite solvent system combining dimethyl amide ether and lactic acid dimethyl amide in specific ratios. This composite solvent system provides enhanced temperature stability that allows high amounts of metalaxyl-M (at least 15% by weight) to be incorporated while maintaining formulation simplicity. The synergistic interaction between the two solvent components achieves temperature stability without requiring additional stabilizing agents or complex formulation structures.

Inventive Principle:
Principle #40Composite materials

Data Source

PatentUS20240196895A1formulation
Publication Date: 2024.06.20 SYNGENTA CROP PROTECITON AG
  • US20240196895A1 patent drawing
  • US20240196895A1 patent drawing

AI summary

This invention relates to a fungicidal composition comprising: a. oxathiapiprolin, b. metalaxyl-M, and c. a lactamide compound of formula I CH3CH(OH)C(═O)NR1R2 (I) wherein R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl, the composition comprising at least 40% by weight of said lactamide compound, over the total weight of the composition.